Literature DB >> 34910799

Treatment of Hyperparathyroidism (SHPT).

Fabiana Rodrigues Hernandes1, Patrícia Goldenstein2, Melani Ribeiro Custódio3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34910799      PMCID： PMC8823921          DOI： 10.1590/2175-8239-JBN-2021-S107

Source DB:  PubMed          Journal:  J Bras Nefrol        ISSN： 0101-2800


× No keyword cloud information.
  41 in total

Review 1.  Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Panpan Cai; Xiaohong Tang; Wei Qin; Ling Ji; Zi Li
Journal:  Int Urol Nephrol       Date:  2016-01-09       Impact factor: 2.370

Review 2.  New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

Authors:  Jorge B Cannata-Andía; Minerva Rodriguez-García; Pablo Román-García; Diego Tuñón-le Poultel; Francisco López-Hernández; Diego Rodríguez-Puyol
Journal:  Pediatr Nephrol       Date:  2010-02-12       Impact factor: 3.714

Review 3.  Parathyroidectomy in the Management of Secondary Hyperparathyroidism.

Authors:  Wei Ling Lau; Yoshitsugu Obi; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-09       Impact factor: 8.237

Review 4.  Renal osteodystrophy in chronic renal failure.

Authors:  L Tammy Ho; Stuart M Sprague
Journal:  Semin Nephrol       Date:  2002-11       Impact factor: 5.299

Review 5.  Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.

Authors:  John Cunningham; Francesco Locatelli; Mariano Rodriguez
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-31       Impact factor: 8.237

Review 6.  Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure.

Authors:  Hartmut H Malluche; Hanna Mawad; Nicholas J Koszewski
Journal:  Kidney Int       Date:  2002-08       Impact factor: 10.612

Review 7.  Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.

Authors:  Dennis L Andress; Daniel W Coyne; Kamyar Kalantar-Zadeh; Mark E Molitch; Farhad Zangeneh; Stuart M Sprague
Journal:  Endocr Pract       Date:  2008 Jan-Feb       Impact factor: 3.443

8.  Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Francesca Tentori; Margaret J Blayney; Justin M Albert; Brenda W Gillespie; Peter G Kerr; Jürgen Bommer; Eric W Young; Tadao Akizawa; Takashi Akiba; Ronald L Pisoni; Bruce M Robinson; Friedrich K Port
Journal:  Am J Kidney Dis       Date:  2008-06-02       Impact factor: 8.860

9.  A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.

Authors:  Michel Chonchol; Francesco Locatelli; Hanna E Abboud; Chaim Charytan; Angel L M de Francisco; Shivinder Jolly; Mark Kaplan; Simon D Roger; Shyamal Sarkar; Moetaz B Albizem; T Christian H Mix; Yumi Kubo; Geoffrey A Block
Journal:  Am J Kidney Dis       Date:  2008-12-24       Impact factor: 8.860

Review 10.  Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.

Authors:  William G Goodman
Journal:  Pediatr Nephrol       Date:  2003-10-28       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.